A randomized, open-label, multi-center phase IV study evaluating palbociclib plus endocrine treatment versus a chemotherapy-based treatment strategy in patients with hormone receptor positive / HER2 negative metastatic breast cancer in a real world setting (PADMA study). GBG 93
Hormon,Zielgerichtet - Therapieart: palliativ